Corteva Q3 Sales Fall 9% to $1.59 Billion on Brazil Weakness; Company Updates 2026 Outlook
Corteva's third-quarter sales fell 9% to $1.59 billion as a sharp slump in Brazil outweighed growth in North America, Europe and Asia, and the crop protection company updated its full-year outlook to reflect what it called weaker-than-expected conditions in that market.
The company swung to a pro forma loss from continuing operations of $54 million, or 8 cents a share, from a $60 million profit a year earlier, according to its earnings release, which was filed with an 8-K on Thursday. Adjusted pro forma operating EPS was 6 cents, down 57%, and adjusted pro forma operating EBITDA fell 17% to $222 million.
These are Corteva's first quarterly results since it spun off its seed business, now Vylor Inc., on Oct. 1, 2026, which is why the company reports on a pro forma basis.
Brazil drove the decline
Organic sales fell 9%, with volume down 2% and price down 7%. The company blamed competitive pressure on molecules late in their lifecycle in Brazil and an expected hit from U.S. acetochlor pricing.
Latin America organic sales dropped 31%, as volume fell 24% on elevated channel inventory and delayed purchasing tied to farmer liquidity constraints and high interest rates. Elsewhere, organic sales rose 7% in North America, where volume jumped 19%, 14% in Europe, the Middle East and Africa, and 5% in Asia Pacific.
"Acetochlor pricing in the U.S. was consistent with our expectations, but Brazil was materially weaker than anticipated," Chief Executive Luke Kissam said in the release.
Updated 2026 outlook
Corteva now expects full-year adjusted pro forma operating EBITDA of $1.1 billion to $1.125 billion and adjusted pro forma operating EPS of 76 to 80 cents. The release attributes the update primarily to deterioration in Brazil and does not restate the prior range.
Through nine months, net sales were $5.36 billion, down 1%, and adjusted pro forma operating EBITDA of $943 million was flat, with margin up 30 basis points to 17.6%. The release also says the board authorized Corteva's first common dividend since the spin-off.
By the numbers
- Q3 net sales: $1.59 billion, down 9%
- Q3 pro forma loss from continuing operations: $54 million, or $0.08 a share
- Q3 adjusted pro forma operating EBITDA: $222 million, down 17%
- Latin America organic sales: down 31%
- 2026 operating EBITDA outlook: $1.1 billion to $1.125 billion
- 2026 operating EPS outlook: $0.76 to $0.80
Sources
- Corteva, Inc., Form 8-K (Item 2.02) with Exhibit 99.1 earnings release, filed Nov. 12, 2026, accession 0001755672-26-000031
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.